Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BRNS
BRNS logo

BRNS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.595
Open
0.521
VWAP
0.56
Vol
4.07K
Mkt Cap
22.47M
Low
0.521
Amount
2.26K
EV/EBITDA(TTM)
--
Total Shares
40.85M
EV
-47.91M
EV/OCF(TTM)
--
P/S(TTM)
--
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Show More

Events Timeline

(ET)
2026-03-13
08:10:00
Barinthus Bio and Clywedog Merger Outlook Positive
select
2025-12-10 (ET)
2025-12-10
08:20:00
Barinthus Biotherapeutics Updates on VTP-1000 Phase 1 Trial Progress
select
2025-11-07 (ET)
2025-11-07
07:33:30
Barinthus Biotherapeutics announces Q3 earnings per share of 36 cents, compared to a loss of 21 cents in the same period last year.
select
2025-09-30 (ET)
2025-09-30
08:20:53
Barinthus Bio and Clywedog Finalize Merger Agreement
select
2025-08-07 (ET)
2025-08-07
08:03:26
Barinthus Biotherapeutics sees cash runway into 2027
select
2025-08-07
08:03:01
Barinthus Biotherapeutics reports Q2 EPS (52c) vs. (49c) last year
select
2025-05-07 (ET)
2025-05-07
08:07:59
Barinthus Biotherapeutics reports Q1 EPS (49c), consensus (36c)
select
2025-03-20 (ET)
2025-03-20
07:28:21
Barinthus Biotherapeutics sees cash runway into 2027
select

News

PRnewswire
8.5
03-16PRnewswire
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
  • Legal Investigation Launched: Halper Sadeh LLC is investigating National Storage Affiliates Trust (NYSE:NSA) for its sale to Public Storage, which offers 0.14 shares of Public Storage stock for each National Storage share, potentially infringing on shareholder rights.
  • Shareholder Rights Protection: Urgent.ly, Inc. (NASDAQ:ULY) is being sold to Agero, Inc. for $5.50 per share, and Halper Sadeh LLC encourages Urgent.ly shareholders to understand their legal rights and options to ensure transaction fairness.
  • Merger Scrutiny: The merger between Esquire Financial Holdings, Inc. (NASDAQ:ESQ) and Signature Bancorporation, Inc. is under review, with Halper Sadeh LLC potentially seeking increased compensation and disclosures for shareholders to protect investor interests.
  • Biotech Merger: The merger agreement between Barinthus Biotherapeutics plc (NASDAQ:BRNS) and Clywedog Therapeutics, Inc. stipulates that Barinthus shareholders will receive one share of common stock in the new company for each share owned, with Halper Sadeh LLC representing shareholders to safeguard their legal rights.
seekingalpha
9.5
03-13seekingalpha
Barinthus Biotherapeutics Financial Report Analysis
  • Financial Performance: Barinthus Biotherapeutics reported a FY GAAP EPS of -$1.64 for 2025, indicating significant challenges in profitability that could undermine investor confidence and affect stock performance.
  • Cash Flow Status: As of December 31, 2025, the company had $71.9 million in cash, cash equivalents, and restricted cash, a sharp decline from $112.4 million as of December 31, 2024, suggesting increased liquidity risk that may limit future investments and operational capabilities.
  • R&D Spending Changes: Research and development expenses decreased to $25.6 million in 2025 from $42.2 million in 2024, reflecting a contraction in R&D investment that could impact future product development and market competitiveness.
  • Market Outlook: With deteriorating financial conditions and reduced R&D spending, Barinthus Biotherapeutics may face greater market pressures, prompting investors to closely monitor its future strategic adjustments and funding plans.
NASDAQ.COM
4.0
2025-12-15NASDAQ.COM
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Receives Upgrade to Buy: Implications for the Stock
  • Zacks Rank Upgrade: Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which could lead to increased stock prices.

  • Earnings Estimate Revisions: The Zacks Consensus Estimate for the company has risen by 1.1% over the past three months, reflecting analysts' growing confidence in its earnings potential.

  • Investment Strategy: The Zacks rating system, which categorizes stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.

  • Market Positioning: The upgrade places Barinthus Biotherapeutics in the top 20% of Zacks-covered stocks, suggesting it is well-positioned for potential market-beating returns in the near term.

Newsfilter
9.0
2025-12-10Newsfilter
Barinthus Bio Reports Positive Progress in Celiac Disease Immunotherapy Trial
  • Clinical Trial Progress: Barinthus Bio's VTP-1000 demonstrated good tolerability in the Phase 1 trial for celiac disease, with no treatment-related serious adverse events reported in the single ascending dose (SAD) portion, indicating both safety and potential efficacy of the therapy.
  • Significant Pharmacological Effects: Among the 18 patients in the SAD phase, a dose-dependent pharmacological effect was observed, suggesting that the therapy can effectively stimulate immune responses, thereby laying the groundwork for future multiple dosing studies that may offer new treatment options for celiac disease patients.
  • Anticipated Follow-Up Research: The ongoing multiple ascending dose (MAD) phase is expected to yield data in the second half of 2026, which will provide critical insights for further validating the efficacy of VTP-1000 and optimizing treatment regimens, potentially transforming the treatment landscape for celiac disease.
  • Substantial Market Potential: With celiac disease affecting approximately 80 million people globally and no approved treatments currently available, the successful development of VTP-1000 could address this high unmet need, presenting significant commercial value and societal impact.
Globenewswire
7.0
2025-11-20Globenewswire
Halper Sadeh LLC Urges HFWA, BRNS, FITB Shareholders to Reach Out for Rights Consultation
  • Investigation of Mergers: Halper Sadeh LLC is investigating potential violations of federal securities laws related to mergers involving Heritage Financial Corporation, Barinthus Biotherapeutics plc, and Fifth Third Bancorp.

  • Shareholder Rights: The firm encourages shareholders from these companies to learn about their rights and options regarding the proposed mergers, which may affect their ownership stakes in the combined entities.

  • Legal Representation: Halper Sadeh LLC offers to represent shareholders on a contingent fee basis, meaning no upfront legal fees are required, and they aim to seek increased consideration or additional disclosures for shareholders.

  • Contact Information: Shareholders can contact Halper Sadeh LLC for free consultations regarding their legal rights, with provided contact details for attorneys Daniel Sadeh and Zachary Halper.

PRnewswire
7.0
2025-11-19PRnewswire
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
  • Investigation of Companies: Halper Sadeh LLC is investigating Barinthus Biotherapeutics, Fifth Third Bancorp, Adverum Biotechnologies, and Huntington Bancshares for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their mergers and acquisitions.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to learn about their legal rights and options, as there may be limited time to enforce these rights.

  • Compensation Structure: The law firm operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees unless the case is successful.

  • Legal Support for Investors: Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to recover funds and implement corporate reforms.

Wall Street analysts forecast BRNS stock price to rise
1 Analyst Rating
Wall Street analysts forecast BRNS stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
4.00
Averages
4.00
High
4.00
Current: 0.000
sliders
Low
4.00
Averages
4.00
High
4.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$3 -> $4
AI Analysis
2025-11-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$3 -> $4
AI Analysis
2025-11-17
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Barinthus Biotherapeutics to $4 from $3 and keeps a Buy rating on the shares following the Q3 report.

Valuation Metrics

The current forward P/E ratio for Barinthus Biotherapeutics PLC (BRNS.O) is -0.50, compared to its 5-year average forward P/E of -1.15. For a more detailed relative valuation and DCF analysis to assess Barinthus Biotherapeutics PLC's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.15
Current PE
-0.50
Overvalued PE
7.71
Undervalued PE
-10.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.60
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.51
Undervalued EV/EBITDA
-3.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
28.42
Current PS
0.00
Overvalued PS
70.98
Undervalued PS
-14.14

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Show me stocks under $2 with growth
Intellectia · 172 candidates
Price: $0.10 - $2.00Annual Eps Yoy Growth: >= 5.0%Annual Revenue Yoy Growth: >= 5.0%
Ticker
Name
Market Cap$
top bottom
PETZ logo
PETZ
TDH Holdings Inc
11.61M
GERN logo
GERN
Geron Corp
871.35M
RETO logo
RETO
ReTo Eco-Solutions Inc
3.44M
LOOP logo
LOOP
Loop Industries Inc
55.10M
ONCO logo
ONCO
Onconetix Inc
2.37M
ZTEK logo
ZTEK
Zentek Ltd
82.63M

Whales Holding BRNS

H
HongShan Capital Advisors Limited
Holding
BRNS
-10.66%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Barinthus Biotherapeutics PLC (BRNS) stock price today?

The current price of BRNS is 0.55 USD — it has increased 0

What is Barinthus Biotherapeutics PLC (BRNS)'s business?

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.

What is the price predicton of BRNS Stock?

Wall Street analysts forecast BRNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRNS is4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Barinthus Biotherapeutics PLC (BRNS)'s revenue for the last quarter?

Barinthus Biotherapeutics PLC revenue for the last quarter amounts to 0.00 USD, decreased

What is Barinthus Biotherapeutics PLC (BRNS)'s earnings per share (EPS) for the last quarter?

Barinthus Biotherapeutics PLC. EPS for the last quarter amounts to -0.27 USD, decreased -47.06

How many employees does Barinthus Biotherapeutics PLC (BRNS). have?

Barinthus Biotherapeutics PLC (BRNS) has 14 emplpoyees as of April 01 2026.

What is Barinthus Biotherapeutics PLC (BRNS) market cap?

Today BRNS has the market capitalization of 22.47M USD.